Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1617127 | 0.97 | ALDH1A1 (0.32) | SLC18A3KDM4EPOLBTSHR | |
| SCHEMBL2148090 | 0.91 | ALDH1A1 (0.37) | SLC18A3KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL6607826 | 0.89 | ALDH1A1 (0.40) | SLC18A3KDM4EPOLB | |
| SCHEMBL10379765 | 0.85 | — | — | |
| SCHEMBL2148202 | 0.85 | ALDH1A1 (0.39) | KDM4E | |
| SCHEMBL4020631 | 0.81 | SLC18A3 (0.34) | SLC18A3 | |
| SCHEMBL15556894 | 0.78 | ALDH1A1 (0.35) | KDM4ETSHR | |
| SCHEMBL22723588 | 0.72 | ALDH1A1 (0.41) | — | |
| SCHEMBL6120938 | 0.70 | SLC18A3 (0.34) | SLC18A3 | |
| SCHEMBL1891737 | 0.70 | SLC18A3 (0.34) | SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499634-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-11878965-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2023192801-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230090053-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-03-23 | — | — | US | disclosed |
| EP-3814338-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7923559-B2 | 7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane; mania, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, Tourette's syndrome | TARGACEPT, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2078718-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | Targacept, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080214591-A1 | N-Aryl Diazaspirocyclic Compounds and Methods of Preparation and Use Thereof | BHATTI BALWINDER S | 2008-09-04 | — | — | US | disclosed |
| US-7375110-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1784184-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | Targacept, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | BHATTI BALWINDER S | 2006-09-28 | — | — | US | disclosed |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | BHATTI BALWINDER S | 2006-03-16 | — | — | US | disclosed |
| WO-2006023630-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | TARGACEPT, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | BHATTI BALWINDER S | 2005-12-08 | — | — | US | disclosed |
| US-6956042-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1519939-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | Targacept, Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004005293-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214591-A1 | N-Aryl Diazaspirocyclic Compounds and Methods of Preparation and Use Thereof | TNNC1, ACHE, CHRNA6 | SLC18A3 65/4885KDM4E 3731/4885POLB 3201/4885 |
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | SLC18A3 65/4885KDM4E 3731/4885POLB 3201/4885 |
| US-20230090053-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | SLC18A3 2514/4885KDM4E 936/4885POLB 866/4885 |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | SLC18A3 65/4885KDM4E 3542/4885POLB 3184/4885 |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | SLC18A3 65/4885KDM4E 3542/4885POLB 3184/4885 |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | OPRD1, OPRK1, OPRL1 | SLC18A3 171/4885KDM4E 1944/4885POLB 1675/4885 |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | SLC18A3 65/4885KDM4E 3542/4885POLB 3184/4885 |
| US-11878965-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | SLC18A3 2514/4885KDM4E 936/4885POLB 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.